摘要
目的:探讨依卡倍特钠联合含铋剂四联疗法在胃溃疡合并幽门螺杆菌(Hp)感染患者中的应用价值。方法:选择2020年1月—2022年1月本院收治的胃溃疡合并Hp感染患者60例,按随机数字表法分为两组。对照组(30例)采用含铋剂四联疗法,饭后口服阿莫西林胶囊1000 mg/次+呋喃唑酮片100 mg/次,1次/12 h,饭前口服艾司奥美拉唑镁肠溶胶囊20 mg/次+枸橼酸铋钾颗粒220 mg/次,2次/d。研究组(30例)在对照组基础上联用依卡倍特钠口服,1000 mg/次,2次/d。两组均治疗14 d。比较两组Hp根除率、临床疗效、胃蛋白酶、血清炎性因子及不良反应。结果:研究组Hp根除率(93.33%)、治疗总有效率(93.33%)高于对照组(73.33%、70.00%)。治疗前两组患者的胃蛋白酶Ⅰ、胃蛋白酶Ⅱ、白介素(IL)-6、肿瘤坏死因子α(TNF-α)和C-反应蛋白(CRP)比较,无统计学差异(P>0.05);治疗后观察组的胃蛋白酶Ⅰ和胃蛋白酶Ⅱ均高于对照组,IL-6、TNF-α和CRP均低于对照组,有统计学差异(P<0.05)。两组不良反应相当,无统计学差异(P>0.05)。结论:依卡倍特钠联合含铋剂四联疗法用于胃溃疡合并Hp感染患者治疗中,能够有效提高Hp根除率及胃蛋白酶水平,减轻炎症反应,且安全性高,临床应用价值更高。
Objective:To investigate the application value of ecabate sodium combined with bismuth-containing quadruple therapy in patients with gastric ulcers complicated with Helicobacter pylori(Hp)infection.Methods:Sixty patients with gastric ulcer complicated with Hp infection admitted to our hospital from January 2020 to January 2022 were divided into two groups according to the random number table method.The control group(30 cases)received bismuth-containing tetrad therapy:amoxicillin capsule 1000 mg/time+furazolidone tablet 100 mg/time once every 12 hours after meals,esomeprazole magnesium enteric-coated capsule 20 mg/time+bismuth potassium citrate granule 220 mg/time,twice/day before meals.The study group(30 cases)was treated with ecabate sodium(1000 mg/time,twice/day)orally based on the control group.Both groups were treated for 14 days.Hp eradication rate,clinical efficacy,pepsin level,serum inflammatory factors,and adverse reactions were compared between the two groups.Results:The Hp eradication rate(93.33%)and total effective rate(93.33%)in the study group were higher than those in the control group(73.33%and 70.00%).Before treatment,the levels of pepsinⅠ,pepsinⅡ,interleukin6(IL-6),tumor necrosis factorα(TNF-α),and C-reactive protein(CRP)in the two groups were compared.There was no significant difference(P>0.05).After treatment,the levels of pepsinⅠand pepsinⅡin the observation group were higher than those in the control group,and the levels of IL-6,TNF-α,and CRP were lower than those in the control group,with statistical differences(P<0.05).There was no significant difference in adverse reactions between the two groups(P>0.05).Conclusions:In treating gastric ulcer patients with Hp infection,ecabate sodium combined with bismuth can effectively improve the eradication rate of Hp and the level of pepsin,reduce inflammation,and have high safety and clinical application value.
作者
周友梅
Zhou Youmei(Pingxiang Second People's Hospital,Jiangxi 337000)
出处
《天津药学》
2023年第5期53-56,共4页
Tianjin Pharmacy
关键词
胃溃疡
幽门螺杆菌感染
含铋剂四联疗法
依卡倍特钠
胃蛋白酶
血清炎性因子
gastric ulcer
helicobacter pylori infection
bismuth containing quadruple therapy
ecabate sodium
pepsin
serum inflammatory factor
